Overview

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.

Phase:

PHASE2

Details

Lead Sponsor:

MBX Biosciences